• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

David P. Steensma, MD


  • Garcia-Manero G, Gartenberg G, Steensma DP, Schipperus MR, Breems DA, de Paz R, Valcárcel D, Kranenburg B, Reddy M, Komrokji RS.A Phase 2, Randomized, Double-blind, Multicenter Study Comparing Siltuximab Plus Best Supportive Care With Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome.Am J Hematol. 2014 May 31.
  • Gafter-Gvili A, Steensma DP, Auerbach M.Should the ASCO/ASH Guidelines for the use of intravenous iron in cancer- and chemotherapy-induced anemia be updated?.J Natl Compr Canc Netw. 2014 May;12(5):657-64.
  • Adamia S, Bar-Natan M, Haibe-Kains B, Pilarski PM, Bach C, Pevzner S, Calimeri T, Avet-Loiseau H, Lode L, Verselis S, Fox EA, Galinsky I, Mathews S, Dagogo-Jack I, Wadleigh M, Steensma DP, Motyckova G, Deangelo DJ, Quackenbush J, Tenen DG, Stone RM, Griffin JD.NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML.Blood. 2014 May 1(18):2816-25.
  • Kantarjian HM, Steensma DP, Light DW.The Patient Protection and Affordable Care Act: Is it good or bad for oncology?.Cancer. 2014 Mar 18.
  • Adamia S, Haibe-Kains B, Pilarski PM, Bar-Natan M, Pevzner S, Avet-Loiseau H, Lode L, Verselis S, Fox EA, Burke J, Galinsky I, Dagogo-Jack I, Wadleigh M, Steensma DP, Motyckova G, Deangelo DJ, Quackenbush J, Stone R, Griffin JD.A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets.Clin Cancer Res. 2014 Mar 1;20(5):1135-45.
  • Steensma DP, Komrokji RS, Stone RM, List AF, Garcia-Manero G, Huber JM, Dennison B, Sekeres MA.Disparity in perceptions of disease characteristics, treatment effectiveness, and factors influencing treatment adherence between physicians and patients with myelodysplastic syndromes.Cancer. 2014 Feb 27.
  • Steensma DP, Kantarjian HM.Impact of cancer research bureaucracy on innovation, costs, and patient care.J Clin Oncol. 2014 Feb 10;32(5):376-8.
  • Steensma DP, Gattermann N.When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?.Best Pract Res Clin Haematol. 2013 Dec;26(4):431-44.
  • Ramsey H, Zhang Q, Brown DE, Steensma DP, Lin CP, Wu MX.Stress-induced hematopoietic failure in the absence of immediate early response gene X-1 (IEX-1, IER3).Haematologica. 2014 Feb;99(2):282-91.
  • Bowen DT, Hellström-Lindberg E, Steensma DP.Cardiac iron overload assessed by T2* magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients.British Journal of Haematology. 2014 Feb;164(4):610-1.
  • Abel GA, Klaassen R, Lee SJ, Young NL, Cannella L, Steensma DP, Efficace F.Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life.Blood. 2014 Jan 16;123(3):451-2.
  • Hartwell KA, Miller PG, Mukherjee S, Kahn AR, Stewart AL, Logan DJ, Negri JM, Duvet M, Järås M, Puram R, Dancik V, Al-Shahrour F, Kindler T, Tothova Z, Chattopadhyay S, Hasaka T, Narayan R, Dai M, Huang C, Shterental S, Chu LP, Haydu JE, Shieh JH, Steensma DP, Munoz B, Bittker JA, Shamji AF, Clemons PA, Tolliday NJ, Carpenter AE, Gilliland DG, Stern AM, Moore MA, Scadden DT, Schreiber SL, Ebert BL, Golub TR.Niche-based screening identifies small-molecule inhibitors of leukemia stem cells.Nat Chem Biol. 2013 Dec;9(12):840-8.
  • Crawford J, Armitage J, Balducci L, Becker PS, Blayney DW, Cataland SR, Heaney ML, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahon B, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Steensma DP, Talbott M, Vadhan-Raj S, Westervelt P, Westmoreland M, Dwyer M, Ho M.Myeloid growth factors.J Natl Compr Canc Netw. 2013 Oct 1;11(10):1266-90.
  • Attar EC, Amrein PC, Fraser JW, Fathi AT, McAfee S, Wadleigh M, Deangelo DJ, Steensma DP, Stone RM, Foster J, Neuberg D, Ballen KK.Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).Leuk Res. 2013 Sep;37(9):1016-20.
  • Steensma DP.The Beginning of the End of the Beginning in Cancer Genomics.N Engl J Med. 2013 May 1.
  • Tothova Z, Steensma DP, Ebert BL.New strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practice.Clin Cancer Res. 2013 Apr 1;19(7):1637-43.
  • Steensma DP.Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?.Best Pract Res Clin Haematol. 2012 Dec;25(4):443-51.
  • Sekeres MA, Steensma DP.Boulevard of broken dreams: drug approval for older adults with acute myeloid leukemia.J Clin Oncol. 2012 Nov 20;30(33):4061-3.
  • Steensma DP.Historical perspectives on myelodysplastic syndromes.Leuk Res. 2012 Dec;36(12):1441-52.
  • Brierley CK, Morgan EA, Sprague JR, Odejide OO, Deangelo DJ, Steensma DP.An extreme example of focal bone marrow involvement in acute myeloid leukemia.Am J Hematol. 2012 Oct 11.
  • Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, Galili N, Raza A, Kantarjian H, Levine RL, Neuberg D, Garcia-Manero G, Ebert BL.Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes.J Clin Oncol. 2012 Sep 20;30(27):3376-82.
  • Ruiz-Argüelles GJ, Gomez-Almaguer D, Steensma DP.Outdated dogma? Busulfan, seizure prophylaxis, and stem cell allografting.Am J Hematol. 2012 Sep;87(9):941.
  • Raza A, Galili N, Mulford D, Smith SE, Brown GL, Steensma DP, Lyons RM, Boccia R, Sekeres MA, Garcia-Manero G, Mesa RA.Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS).J Hematol Oncol. 2012;5:18.
  • Steensma DP.Tuning the rigging before sailing off into the stormy sea of stem cell transplants for patients with myelodysplastic syndromes.Biol Blood Marrow Transplant. 2012 Aug;18(8):1145-7.
  • List AF, Baer MR, Steensma DP, Raza A, Esposito J, Martinez-Lopez N, Paley C, Feigert J, Besa E.Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome.J Clin Oncol. 2012 Jun 10;30(17):2134-9.
  • Baumann Kreuziger LM, Wolanskyj AP, Hanson CA, Steensma DP.Lack of efficacy of pyridoxine (vitamin B6) treatment in acquired idiopathic sideroblastic anaemia, including refractory anaemia with ring sideroblasts.Eur J Haematol. 2011 Mar 9.
  • Steensma DP.ASH 2010 meeting report-Top 10 clinically-oriented abstracts in myelodysplastic syndromes (MDS).Am J Hematol. 2011 Apr;86(4):385-91.
  • Steensma DP.The Relevance of Iron Overload and the Appropriateness of Iron Chelation Therapy for Patients with Myelodysplastic Syndromes: A Dialogue and Debate.Curr Hematol Malig Rep. 2011 Mar 5.
  • Steensma DP.The role of iron chelation therapy for patients with myelodysplastic syndromes.J Natl Compr Canc Netw. 2011 Jan;9(1):65-75.
  • Steensma DP, Sloan JA, Dakhil SR, Dalton R, Kahanic SP, Prager DJ, Stella PJ, Rowland KM, Novotny PJ, Loprinzi CL.Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia.J Clin Oncol. 2011 Jan 1;29(1):97-105.
  • Thapaliya P, Tefferi A, Pardanani A, Steensma DP, Camoriano J, Wu W, Geyer S, Mesa RA.International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens.Am J Hematol. 2011 Jan;86(1):96-8.
  • Davids MS, Steensma DP.The molecular pathogenesis of myelodysplastic syndromes.Cancer Biol Ther. 2010 Aug;10(4):309-19.
  • Loprinzi CL, Schapira L, Moynihan T, Kalemkerian GP, von Gunten C, Steensma D.Compassionate honesty.J Palliat Med. 2010 Oct;13(10):1187-91.
  • Steensma DP, Kyle RA, Shampo MA.Walter Clement Noel—first patient described with sickle cell disease.Mayo Clin Proc. 2010 Oct;85(10):e74-5.
  • Steensma DP.A cello for michayla.J Clin Oncol. 2010 Oct 1;28(28):4400-1.
  • Shampo MA, Kyle RA, Steensma DP.Stamp vignette on medical science. Robert F. Curl Jr-Nobel Laureate in Chemistry.Mayo Clin Proc. 2010 Aug;85(8):e58.
  • Steensma DP.The scent of cancer.Ann Intern Med. 2010 Aug 3;153(3):206-7.
  • Steensma DP.P39/Tsugane cells are a false cell line contaminated with HL-60 cells and are not suitable for mechanistic studies in myelodysplastic syndromes.Haematologica. 2010 Jul;95(7):1229-30.
  • Shampo MA, Kyle RA, Steensma DP.Edward L. Trudeau--founder of a sanatorium for treatment of tuberculosis.Mayo Clin Proc. 2010 Jul;85(7):e48.
  • Steensma DP.Novel therapies for myelodysplastic syndromes.Hematol Oncol Clin North Am. 2010 Apr;24(2):423-41. Review.
  • Steensma DP, Stone RM.Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes.Hematol Oncol Clin North Am. 2010 Apr;24(2):389-406. Review.
  • Calvin AD, Somers VK, Steensma DP, Rio Perez JA, van der Walt C, Fitz-Gibbon JM, Scott CG, Olson LJ.Advanced heart failure and nocturnal hypoxaemia due to central sleep apnoea are associated with increased serum erythropoietin.Eur J Heart Fail. 2010 Apr;12(4):354-9.
  • Jacobs NL, Holtan SG, Porrata LF, Markovic SN, Tefferi A, Steensma DP.Host immunity affects survival in myelodysplastic syndromes: Independent prognostic value of the absolute lymphocyte count.Am J Hematol. 2010 Mar;85(3):160-3.
  • Steensma DP.P39/Tsugane cells are a false cell line contaminated with HL-60 cells and are not suitable for mechanistic studies in myelodysplastic syndromes.Haematologica. 2010 Feb 23.
  • Steensma DP.Decitabine treatment of patients with higher-risk myelodysplastic syndromes.Leuk Res. 2009 Dec;33 Suppl 2:S12-7.
  • Steensma DP.ACP Journal Club. Anemia was independently associated with mortality in very old persons.Ann Intern Med. 2009 Dec 15;151(12):JC6-13.
  • Steensma DP, Neiger JD, Porcher JC, Keats JJ, Bergsagel PL, Dennis TR, Knudson RA, Jenkins RB, Santana-Davila R, Kumar R, Ketterling RP.Rearrangements and amplification of IER3 (IEX-1) represent a novel and recurrent molecular abnormality in myelodysplastic syndromes.Cancer Res. 2009 Oct 1;69(19):7518-23.
  • Sekeres MA, Steensma DP.Defining prior therapy in myelodysplastic syndromes and criteria for relapsed and refractory disease: implications for clinical trial design and enrollment.Blood. 2009 Sep 24;114(13):2575-80. Review.
  • Steensma DP.Out of this nettle, danger, we must pluck this flower, safety.Blood. 2009 Sep 17;114(12):2364-5.
  • Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA, Garcia-Manero G, Albitar M, Larsen JS, Arora S, Cullen MT, Kantarjian H.Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial.J Clin Oncol. 2009 Aug 10;27(23):3842-8.
  • Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J, Pardanani AD, Steensma DP, Litzow MR, Rivera CE, Camoriano J, Verstovsek S, Sloan J, Harrison C, Kantarjian H, Tefferi A.The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis.Leuk Res. 2009 Sep;33(9):1199-203.
  • Steensma DP.Myelodysplasia paranoia: iron as the new radon.Leuk Res. 2009 Sep;33(9):1158-63.
  • Steensma DP, Porcher JC, Litzow MR, Hogan WJ, Arora S, Van Laar ES.Assessment of ATRX expression in patients with myelodysplastic syndromes treated with decitabine.Leuk Res. 2009 Jul;33(7):e81-2.
  • Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, Piper M, Rades D, Steensma DP, Djulbegovic B, Fey MF, Ray-Coquard I, Machtay M, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A.Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.Lancet. 2009 May 2;373(9674):1532-42.
  • Wardrop D, Steensma DP.Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T) a necessary or useful diagnostic category?.British Journal of Haematology. 2009 Mar;144(6):809-17. Review.
  • Caudill JS, Imran H, Porcher JC, Steensma DP.Congenital sideroblastic anemia associated with germline polymorphisms reducing expression of FECH.Haematologica. 2008 Oct;93(10):1582-4.
  • Baumann Kreuziger LM, Steensma DP.RAD51 and XRCC3 polymorphism frequency and risk of myelodysplastic syndromes.Am J Hematol. 2008 Oct;83(10):822-3.
  • Steensma DP.Investment analysts and the American Society of Hematology.Blood. 2008 Jul 1;112(1):29-33.
  • Steensma DP, Heptinstall KV, Johnson VM, Novotny PJ, Sloan JA, Camoriano JK, Niblack J, Bennett JM, Mesa RA.Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey.Leuk Res. 2008 May;32(5):691-8.
  • Palmer SR, Tefferi A, Hanson CA, Steensma DP.Platelet count is an IPSS-independent risk factor predicting survival in refractory anaemia with ringed sideroblasts.British Journal of Haematology. 2008 Mar;140(6):722-5.
  • Steensma DP, Porcher JC, Hanson CA, Lathrop CL, Hoyer JD, Lasho TA, Tefferi A, Higgs DR.Prevalence of erythrocyte haemoglobin H inclusions in unselected patients with clonal myeloid disorders.British Journal of Haematology. 2007 Nov;139(3):439-42.
  • White JG, Nichols WL, Steensma DP.Platelet pathology in sex-linked GATA-1 dyserythropoietic macrothrombocytopenia II. Cytochemistry.Platelets. 2007 Sep;18(6):436-50.
  • Steensma DP, Friday BB.Monocytic skin nodules in chronic myelomonocytic leukemia: clinical response to decitabine therapy.Leuk Lymphoma. 2007 Aug;48(8):1628-9.
  • Steensma DP, Tefferi A.Anemia in the elderly: how should we define it, when does it matter, and what can be done?.Mayo Clin Proc. 2007 Aug;82(8):958-66. Review.
  • Steensma DP.Are myelodysplastic syndromes "cancer"? Unexpected adverse consequences of linguistic ambiguity.Leuk Res. 2006 Oct;30(10):1227-33. Review.
  • Steensma DP, Pardanani A, Stevenson WS, Hoyt R, Kiu H, Grigg AP, Szer J, Juneja S, Hilton DJ, Alexander WS, Roberts AW.More on Myb in myelofibrosis: molecular analyses of MYB and EP300 in 55 patients with myeloproliferative disorders.Blood. 2006 Feb 15;107(4):1733-5; author reply 1735.
  • Nelson ME, Thurmes PJ, Hoyer JD, Steensma DP.A novel 5' ATRX mutation with splicing consequences in acquired alpha thalassemia-myelodysplastic syndrome.Haematologica. 2005 Nov;90(11):1463-70.
  • Tefferi A, Lasho TL, Schwager SM, Steensma DP, Mesa RA, Li CY, Wadleigh M, Gary Gilliland D.The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.British Journal of Haematology. 2005 Nov;131(3):320-8.
  • Tefferi A, Sirhan S, Lasho TL, Schwager SM, Li CY, Dingli D, Wolanskyj AP, Steensma DP, Mesa R, Gilliland DG.Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia.British Journal of Haematology. 2005 Oct;131(2):166-71.
  • Steensma DP, List AF.Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity.Mayo Clin Proc. 2005 May;80(5):681-98.
  • Steensma DP, Dewald GW, Lasho TL, Powell HL, McClure RF, Levine RL, Gilliland DG, Tefferi A.The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.Blood. 2005 Aug 15;106(4):1207-9.
  • Steensma DP.Down syndrome in Down House: trisomy 21, GATA1 mutations, and Charles Darwin.Blood. 2005 Mar 15;105(6):2614-6.
  • Steensma DP, Gibbons RJ, Higgs DR.Acquired alpha-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies.Blood. 2005 Jan 15;105(2):443-52.
  • Steensma DP, Gibbons RJ, Mesa RA, Tefferi A, Higgs DR.Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia.Eur J Haematol. 2005 Jan;74(1):47-53.
  • Steensma DP, Higgs DR, Fisher CA, Gibbons RJ.Acquired somatic ATRX mutations in myelodysplastic syndrome associated with alpha thalassemia (ATMDS) convey a more severe hematologic phenotype than germline ATRX mutations.Blood. 2004 Mar 15;103(6):2019-26.
  • Steensma DP, Viprakasit V, Hendrick A, Goff DK, Leach J, Gibbons RJ, Higgs DR.Deletion of the alpha-globin gene cluster as a cause of acquired alpha-thalassemia in myelodysplastic syndrome.Blood. 2004 Feb 15;103(4):1518-20.